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portion
Proportion
vaccinated
Deaths vaccine Deaths placebo
(15.6%) 176 (41.6%) 25/176 (14.2%) 41/247 (16.6%)
(14.1%) 195 (50.0%) 32/195 (16.4%) 23/195 (11.8%)
(5.3%) 424 (49.8%) 23/424 (5.4%) 22/427 (5.2%)
(5.3%) 179 (45.1%) 7/179 (3.9%) 14/218 (6.4%)
(4.0%) 579 (52.6%) 21/579 (3.6%) 23/522 (4.4%)
(7.3%) 1553 (49.1%) 108/1553 (7.0%) 123/1609 (7.6%)
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Predominates generalized tetanus and infectious complica-
tions. High mortality.
doi:10.1016/j.ijid.2010.02.49914th International Congress on Infectious Diseases (ICID) Abs
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Background: The long-term outcome following ALRI at a
young age is poorly described. Hypothesizing that ALRI with
X-ray diagnosed pneumonia is associated with worse out-
come, we described the mortality experience until 6 years
of age of a sample of participants in a pneumococcal vaccine
trial.
Methods: Trial follow-up ended at age 2.5 years. We
followed 3920 trial survivors. Five groups were deﬁned by
exposures during the trial: 1. Severe ALRI with X-ray end-
point consolidation (SALRI-EPC), 2. Severe ALRI without EPC
(SALRI-no EPC), 3. Mild ALRI with EPC (MALRI-EPC), 4. Mild
ALRI without EPC (MALRI-no EPC), and 5. Controls without
ALRI or admission. We calculated incidence proportion of
mortality from trial end until follow-up.
Results: In 2008-9, 3367 (85.9%) participants were
traced. Complete data were available for 3162 (80.7%). Mor-
tality was greater among those with SALRI-EPC compared to
controls and greater among those with past SALRI compared
to MALRI, irrespective of radiological ﬁndings (see table).
Confounding by vaccination status was not evident as the
crude relative risk of mortality for SALRI-EPC compared to
no ALRI (3.72; 90% CI 2.82, 4.92) was similar to analysis
stratiﬁed by vaccination status, 3.70; 90% CI 2.80, 4.89.
Follow-up groups: number of deaths, proportion vacci-
nated & deaths by vaccine allocation
Participant
category
Number
traced/sampled
Sex (% Male) Inc
pro
SALRIEPC 423/499 (84.8%) 242 (57.2%) 66
SALRI-no EPC 390/480 (81.3%) 212 (54.4%) 55
MALRIEPC 851/1020 (83.4%) 451 (53.0%) 45
MALRI-no EPC 397/503 (78.9%) 199 (50.1%) 21
No ALRI 1101/1418 (77.6%) 568 (51.6%) 44
Total 3162/3920 (80.7%) 1672 (52.9%) 231
Conclusion: ALRI-EPC <2.5 years of age was associated
with 3.7 times the risk of mortality until 6 years of age,
while compared to MALRI or no ALRI, SALRI was also associ-
ated with increased mortality. SALRI at a young age may be
associated with a predisposition to life threatening illness.
doi:10.1016/j.ijid.2010.02.498ts e395
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etanus: Clinical and epidemiological characteristics.
eview of 11 years
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Background: Tetanus is an infection disease, caused by
he neurological toxicity of tetanoplasmina, exotoxin pro-
uced by Clostridium tetani. Although it is a preventable
isease through vaccination, there are about 100 cases
nnually.
Methods: A retrospective study and analysis of patients
ith tetanus, made in the Rawson Hospital in Córdoba city,
uring the period covered between May 1, 1998 and October
0, 2009. Inclusion criteria: patients with age> 15 years,
linical diagnosis of tetanus.
Results: The incidence was 0.33 per 100,000; average 1.4
ases per year. Of the 12 cases analyzed, 58.3% were men,
verage age 68.5 years. 50% had incomplete immunization
nd 50% had no immunization records. 100% of the patients
resented as generalized tetanus. Port of entry was deter-
inate in 75%: skin lesions predominate in the lower limbs.
ncubation period of less than 7 days and a period of invasion
ess than 48 hours in 66%. Symptoms more common: trismus
00%, dysphagia 91%, generalized muscle contracture 83%,
uscle spasms 58%. Complications: Ventilator-associated
neumonia 50%, atelectasis 33%, scarring 25%. Treatment:
2% received penicillin G sodium, 42% metronidazole and
6% both antimicrobials. Mortality 75%.
Conclusion: Lower incidence. Predominantly found in
lderly men. Lack of veriﬁable previous vaccination.
